These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

207 related items for PubMed ID: 10474114

  • 1. Osteoprotegerin ligand and osteoprotegerin: novel implications for osteoclast biology and bone metabolism.
    Hofbauer LC.
    Eur J Endocrinol; 1999 Sep; 141(3):195-210. PubMed ID: 10474114
    [No Abstract] [Full Text] [Related]

  • 2. [Osteoprotegrin and RANKL/RANK system: is it the future of bone metabolism?].
    Ferrer Cañabate J, Tovar I, Martínez P.
    An Med Interna; 2002 Aug; 19(8):385-88. PubMed ID: 12244784
    [No Abstract] [Full Text] [Related]

  • 3. Osteoprotegerin-receptor activator of nuclear factor-kappaB ligand ratio: a new approach to osteoporosis treatment?
    Coetzee M, Kruger MC.
    South Med J; 2004 May; 97(5):506-11. PubMed ID: 15180028
    [Abstract] [Full Text] [Related]

  • 4. Bone remodelling: a signalling system for osteoclast regulation.
    Filvaroff E, Derynck R.
    Curr Biol; 1998 Sep 24; 8(19):R679-82. PubMed ID: 9768352
    [Abstract] [Full Text] [Related]

  • 5. [Role of receptor activator of nuclear factor kappa B (RANK), its ligand (RANK-L) and osteoprotegerin (OPG) in bone metabolism].
    Stajszczyk M.
    Pol Arch Med Wewn; 2002 Sep 24; 108(3):915-24. PubMed ID: 12600190
    [No Abstract] [Full Text] [Related]

  • 6. RANK ligand and osteoprotegerin: paracrine regulators of bone metabolism and vascular function.
    Schoppet M, Preissner KT, Hofbauer LC.
    Arterioscler Thromb Vasc Biol; 2002 Apr 01; 22(4):549-53. PubMed ID: 11950689
    [Abstract] [Full Text] [Related]

  • 7. Osteoprotegerin: a physiological and pharmacological inhibitor of bone resorption.
    Kostenuik PJ, Shalhoub V.
    Curr Pharm Des; 2001 May 01; 7(8):613-35. PubMed ID: 11375772
    [Abstract] [Full Text] [Related]

  • 8. [Molecular mechanism of bone metabolism].
    Kotake S, Utagawa N, Suda T, Kamatani N.
    Nihon Naika Gakkai Zasshi; 2000 Oct 10; 89(10):2046-53. PubMed ID: 11215116
    [No Abstract] [Full Text] [Related]

  • 9. [Osteoprotegerin ligand and osteoprotegerin: new concepts of the pathogenesis and therapy of metabolic bone diseases].
    Hofbauer LC, Heufelder AE.
    Dtsch Med Wochenschr; 2001 Feb 09; 126(6):145-50. PubMed ID: 11233883
    [No Abstract] [Full Text] [Related]

  • 10. Regulation of bone cell development and function: implication for renal osteodystrophy.
    Disthabanchong S, González EA.
    J Investig Med; 2001 May 09; 49(3):240-9. PubMed ID: 11352181
    [No Abstract] [Full Text] [Related]

  • 11. Disabling of receptor activator of nuclear factor-kappaB (RANK) receptor complex by novel osteoprotegerin-like peptidomimetics restores bone loss in vivo.
    Cheng X, Kinosaki M, Takami M, Choi Y, Zhang H, Murali R.
    J Biol Chem; 2004 Feb 27; 279(9):8269-77. PubMed ID: 14679212
    [Abstract] [Full Text] [Related]

  • 12. Osteoprotegerin, RANK, RANKL.
    Stejskal D, Bartek J, Pastorková R, Růzicka V, Oral I, Horalík D.
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2001 Dec 27; 145(2):61-4. PubMed ID: 12426773
    [Abstract] [Full Text] [Related]

  • 13. Pathophysiology of RANK ligand (RANKL) and osteoprotegerin (OPG).
    Hofbauer LC.
    Ann Endocrinol (Paris); 2006 Apr 27; 67(2):139-41. PubMed ID: 16639364
    [No Abstract] [Full Text] [Related]

  • 14. Osteoprotegerin and receptor activator of nuclear factor kappaB ligand (RANKL) regulate osteoclast formation by cells in the human rheumatoid arthritic joint.
    Haynes DR, Crotti TN, Loric M, Bain GI, Atkins GJ, Findlay DM.
    Rheumatology (Oxford); 2001 Jun 27; 40(6):623-30. PubMed ID: 11426018
    [Abstract] [Full Text] [Related]

  • 15. Osteoprotegerin and its cognate ligand: a new paradigm of osteoclastogenesis.
    Hofbauer LC, Heufelder AE.
    Eur J Endocrinol; 1998 Aug 27; 139(2):152-4. PubMed ID: 9724069
    [No Abstract] [Full Text] [Related]

  • 16. Cross-talk between the interleukin-6 and prostaglandin E(2) signaling systems results in enhancement of osteoclastogenesis through effects on the osteoprotegerin/receptor activator of nuclear factor-{kappa}B (RANK) ligand/RANK system.
    Liu XH, Kirschenbaum A, Yao S, Levine AC.
    Endocrinology; 2005 Apr 27; 146(4):1991-8. PubMed ID: 15618359
    [Abstract] [Full Text] [Related]

  • 17. [Recent advance in basic research for osteoporosis].
    Suda T, Miyaura C.
    Nihon Rinsho; 2004 Feb 27; 62 Suppl 2():13-20. PubMed ID: 15035090
    [No Abstract] [Full Text] [Related]

  • 18. Bone metabolism and growth hormone deficiency. Experimental and clinical aspects.
    Ueland T, Bollerslev J.
    Front Horm Res; 2005 Feb 27; 33():146-160. PubMed ID: 16166760
    [No Abstract] [Full Text] [Related]

  • 19. [A new paradigm of osteoclast biology: discovery of OCIF and ODF].
    Yasuda H.
    Seikagaku; 2000 Jul 27; 72(7):507-25. PubMed ID: 10967683
    [No Abstract] [Full Text] [Related]

  • 20. Regulation of vascular calcification by osteoclast regulatory factors RANKL and osteoprotegerin.
    Collin-Osdoby P.
    Circ Res; 2004 Nov 26; 95(11):1046-57. PubMed ID: 15564564
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.